Comparative pharmacokinetics of SCE-2787 and related antibiotics in experimental animals.
The pharmacokinetic properties of SCE-2787 administered intravenously at a dose of 20 mg/kg of body weight were studied with mice, rats, rabbits, dogs, and monkeys and were compared with those of ceftazidime, cefpirome, and cefclidin in mice and dogs. The area under the concentration-time curve for plasma after intravenous administration was the largest in monkeys, followed by those in dogs, rabbits, rats, and mice, in that order. The elimination half-life ranged from 0.2 to 0.3 h in mice and rats to 0.7 to 1.3 h in rabbits, dogs, and monkeys. In young dogs, the concentrations of SCE-2787 in plasma were somewhat lower than those in the mature dogs. SCE-2787 was distributed well to the tissues, and the highest concentration was found in the kidneys in all species tested; the distribution to the lungs, liver, and spleen was also good, but the concentrations in these tissues were lower than those in the plasma. The pharmacokinetic parameters and urinary excretion of SCE-2787 in mice and dogs were similar to those of ceftazidime, cefpirome, and cefclidin. The maximum concentrations in the cerebrospinal fluid of rats and rabbits were 0.8 and 1.3 micrograms/ml, and the relative percentages of the area under the concentration-time curve of SCE-2787 in the cerebrospinal fluid to that in the plasma were 4.6 and 6.4%, respectively. SCE-2787 was excreted mainly in the urine; the recovery rate ranged from 74% (rats) to 90% (dogs) of the dose. The biliary excretion of SCE-2787, however, was low, amounting to about 1.4% for mice and rats and less than 0.5% for rabbits and dogs. In rats, there was no accumulation in the tissues and no delay in urinary excretion upon multiple intravenous administration of 20 mg of SCE-2787 per kg once daily for 7 days. No active metabolites were found in the plasma or urine of animals given SCE-2787. The binding of SCE-2787 to serum protein in mice, rats, dogs, monkeys, and humans was less than 11% and similar to that of cefclidin.
Kita
Y
Y
Biology Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, Japan.
Yamazaki
T
T
Imada
A
A
D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics*; D001659:Biliary Tract / Q000378:metabolism; D001798:Blood Proteins / Q000378:metabolism; D002442:Ceftazidime / Q000493:pharmacokinetics; D002511:Cephalosporins / Q000493:pharmacokinetics*; D004285:Dogs; D004334:Drug Administration Schedule; D005260:Female; D008252:Macaca fascicularis; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D011485:Protein Binding; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D013045:Species Specificity; D000097572:Cefpirome; D000097586:Cefozopran
D000900:Anti-Bacterial Agents; D001798:Blood Proteins; D002442:Ceftazidime; D002511:Cephalosporins; D000097572:Cefpirome; D000097586:Cefozopran; C056494:cefclidin